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STUDY HIGHLIGHTS 
Current Knowledge 
• The risk of relapse after anti-TNF withdrawal are not well known.
• The variables that impact clinical course after withdrawal are not well known.
• The efficacy and safety of retreatment with the same anti-TNF drug in patients who
relapse seem to be high.
• Currently available data are insufficient to make recommendations on when anti-TNF
therapy can be stopped.
What is new here 
• Approximately half of the patients who discontinued anti-TNF agents because of
clinical remission relapse after discontinuation.
• Treatment with ADA, elective discontinuation of anti-TNF drugs, and discontinuation
due to adverse events increase the risk of relapse.
• Treatment with IMMs and older age at discontinuation are associated with a lower risk
of relapse.
• Discontinuation of anti-TNF therapy cannot be universally recommended. However,
some patients can stop anti-TNF therapy safely and remain in remission for long
periods.
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SUMMARY 
AIMS: To assess the risk of relapse after discontinuation of anti-TNF drugs in patients 
with inflammatory bowel disease, to identify the factors associated with relapse, and to 
evaluate the response to and safety of retreatment with the same anti-TNF after relapsing. 
METHODS: Retrospective, observational, multicentre study. Patients with Crohn’s 
disease or ulcerative colitis who had been treated with anti-TNFs and in whom these drugs 
were discontinued after clinical remission was achieved were included.  
RESULTS: 1,055 patients were included. The cumulative incidence of relapse was 44%: 
24% at 1 year, 38% at 2 years, 46% at 3 years, and 56% at 5 years after anti-TNF 
discontinuation. The incidence rate of relapse was 18% per patient-year. The variables 
associated with a higher risk of relapse were treatment with adalimumab vs. infliximab 
(HR=1.29;95%CI=1.03-1.60) and elective discontinuation of anti-TNFs 
(HR=1.82;95%CI=1.19-2.79) or discontinuation due to adverse events 
(HR=1.95;95%CI=1.22-3.12) vs. a top-down strategy. Treatment with immunomodulators 
after discontinuation (HR=0.70;95%CI=0.57-0.88) and age (HR=0.99;95%CI=0.98-0.99) 
were associated with a lower risk of relapse. Retreatment of relapse with the same anti-TNF 
was effective (88% responded) and safe. 
CONCLUSIONS: The incidence rate of relapse after anti-TNF discontinuation in patients 
with inflammatory bowel disease who were in remission was 18% per patient-year. Treatment 
with adalimumab, the elective discontinuation of anti-TNFs, or discontinuation of anti-TNFs 
due to adverse events (vs. top-down strategy) increased the risk of relapse. Older age and 
maintenance treatment with immunomodulators were associated with a lower risk of relapse. 
Retreatment with the same anti-TNF drug was effective and safe. 
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INTRODUCTION 
Anti-tumour necrosis factor-α (anti-TNF) drugs are effective in inducing and maintaining 
remission in patients with inflammatory bowel diseases (IBD), namely, Crohn's disease (CD) 
and ulcerative colitis (UC)1. This effectiveness is associated with mucosal healing, improved 
quality of life, fewer hospitalizations, and reduced need for surgical procedures1-4. 
Discontinuation of anti-TNF treatment can be considered once remission has been 
achieved. The decision to discontinue anti-TNF drugs in patients in remission depends on 
several factors, such as the cost of the medications, the potential but serious adverse effects, 
and the outcome following elective withdrawal5. Once it has been decided that the drug is to 
be withdrawn, the optimal time for doing so must be established6.  
Studies evaluating this strategy are mostly single-cohort designs, and most of them include 
a small number of patients and have a short follow-up period7. Therefore, the risk of relapse 
after withdrawal of anti-TNF medication and the variables that impact clinical course after 
withdrawal are not well known. Data from small observational studies of patients who 
discontinued anti-TNF therapy after having achieved clinical remission show that the range of 
relapse rates is wide8-14.  
The retreatment with the same anti-TNF drug in patients ho relapse after the initial 
withdrawal have been reported to be apparently successful and safe12, 15-17, and these factors are 
essential before deciding whether to discontinue anti-TNF therapy. However, there are many 
concerns relating to discontinuation of anti-TNF therapy in IBD patients that include not only 
the risk of relapse, but the possible loss of efficacy when the drug is restarted, the risk of 
infusion reactions and other adverse events at retreatment, and, finally, the possibility of 
losing therapeutic options. Therefore, currently available data are insufficient to make 
recommendations on when, if ever, anti-TNF therapy can be stopped in patients with IBD.  
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The aims of the present study were to assess the risk of relapse after discontinuation of anti-
TNF therapy, to identify the factors associated with relapse, to know the rate of response to 
retreatment with the same anti-TNF drug after relapsing, and to evaluate the safety of retreatment 
with these drugs. 
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METHODS 
Study population 
The present study was a multicentre, observational, retrospective study conducted at 78 
Spanish centres. The study population comprised patients diagnosed with CD or UC who had 
been treated with anti-TNF agents (infliximab [IFX] or adalimumab [ADA]) to induce 
remission and in whom these drugs had been discontinued after clinical remission was 
achieved. The reasons for discontinuation of anti-TNF treatment were as follows: elective 
decision (by the physician and/or by the patient), onset of adverse events, and early 
introduction of thiopurines combined with an anti-TNF agent in order to induce clinical 
remission of IBD in patients who were naïve to immunosuppressive therapy (top-down 
strategy). The minimum requirement for all patients was to have received induction treatment 
with anti-TNF drugs. The patients were followed for a minimum of 6 months after stopping 
treatment. Patients who had been treated with anti-TNF drugs for reasons other than IBD or 
with less than 6 months of follow-up after discontinuation was excluded. If the patients had 
more than one attempt to stop the anti-TNF treatment, only the first attempt to discontinue 
this drug was included in analysis. 
Ethical aspects 
The study was approved by the respective institutional ethics review boards, and was 
conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines. 
Data collection 
All clinical, endoscopic, and radiological data were obtained from medical records. The 
data collected included demographic data, duration of IBD, smoking habits, previous surgery 
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for IBD, and previous IBD treatments (eg, immunosuppressants). Clinical, endoscopic, 
laboratory, and radiological data were collected at 3 different times during follow-up: at 
discontinuation of the anti-TNF drug, when the patient relapsed (if this occurred), and at the 
last follow-up visit. It was considered that the patient had an endoscopy or a MRI at the 
moment of withdrawal if these procedures were performed within 30 days before anti-TNF 
discontinuation. Information about the response to treatment after re-introduction of anti-TNF 
therapy in relapsing patients and occurrence of adverse events after reintroduction were also 
recorded.  
Study data were collected and managed using REDCap electronic data capture tools hosted 
at Asociación Española de Gastroenterología (AEG; www.aegastro.es)18. AEG is a non-profit 
Scientific and Medical Society focused on Gastroenterology, and it provided this service free 
of charge, with the sole aim of promoting independent investigator driven research. REDCap 
(Research Electronic Data Capture) is a secure, web-based application designed to support 
data capture for research studies, providing 1) an intuitive interface for validated data entry; 
2) audit trails for tracking data manipulation and export procedures; 3) automated export
procedures for seamless data downloads to common statistical packages; and 4) procedures 
for importing data from external sources.  
Definitions 
Clinical remission: For luminal CD, remission was defined as a Harvey-Bradshaw index 
score ≤ 4 points19. For UC, remission was defined as a partial Mayo score ≤ 2 points20.  In the 
case of perianal disease, remission was defined as the absence of fistula drainage despite 
gentle finger compression (Fistula Drainage Assessment score)21. Given the retrospective 
nature of the study, Harvey-Bradshaw index and partial Mayo score were estimated after 
reviewing the medical records.  
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Endoscopic inflammation: In the case of luminal CD, endoscopic activity was classified 
as mild, moderate, severe, or mucosal healing, as judged by the investigators based on the 
findings in the endoscopy report.  
Given the retrospective design of the study, it was not feasible to calculate endoscopic 
scores based on the endoscopy records. The Rutgeerts index was used to categorize the 
severity of post-surgical recurrence22. Endoscopic inflammation in UC patients was classified 
using the endoscopic subscore of the Mayo index, that was applied retrospectively to 
individual patient reports23. 
Radiological remission: For perianal CD, the disease was considered to be in remission if 
pelvic magnetic resonance imaging (MRI) demonstrated that the perianal fistulas tracts 
showed no signs of activity and were without local complications. In the case of luminal CD 
patients, the disease was considered to be inactive if the abdominal MRI did not show 
contrast enhancement of the wall, oedema, or ulcers.  
Relapse: As this is a retrospective study, relapse was defined as the onset of documented 
clinical, biochemical, endoscopic, or radiological activity leading to a therapeutic 
intervention, namely, escalation or modification of medical therapy or surgery for disease 
control.  
Response to re-treatment: In patients with luminal CD, remission was defined as a 
Harvey-Bradshaw index ≤ 4 points: a partial response was defined as a decrease ≥ 3 points 
from baseline. In fistulising CD, remission was defined as cessation of spontaneous fistula 
drainage and lack of drainage after gentle finger compression, while a decrease from baseline 
in the number of open draining fistulae of ≥ 50% or a reduction in fistula drainage were 
considered partial response. In UC patients, remission was defined as a partial Mayo score ≤ 2 
points, whereas a decrease of ≥ 3 points from baseline was considered a partial response. 
Response to retreatment with anti-TNF therapy was evaluated at 2 time points: 14 weeks 
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(initial response) and the end of follow-up (final response). 
Statistical analysis 
The descriptive analysis of quantitative variables included the mean and standard deviation 
or the median and interquartile range, depending on whether the variables were normally 
distributed or not. For the categorical variables, the percentage and the 95% confidence 
intervals (95% CIs) were provided. Comparisons between means were performed using the t 
test for independent samples. Categorical variables were compared using the χ2 test and the 
Fisher exact test or the Wilcoxon rank-sum test according to the distribution of data. 
Statistical significance was set at P < 0.05.  
Long-term maintenance of remission was estimated using Kaplan-Meier curves. Survival 
curves assessing the impact of several variables on long-term remission were compared using 
the log-rank test. A Cox regression model was constructed to identify predictive factors for 
relapse. All the variables that reached statistical significance in the univariate analysis and 
those that were considered clinically relevant were included in the multivariate analysis. The 
dependent variable was the risk of relapse after discontinuation of anti-TNF therapy. The 
independent variables were: type of IBD (CD and UC), gender, age at discontinuation 
(included as a continuous variable), surgery due to IBD, current smoking habit, type of anti-
TNF drug received (IFX or ADA), duration of anti-TNF treatment, reasons for anti-TNF 
discontinuation (elective discontinuation, discontinuation due to adverse events, and 
discontinuation as a part of a top-down strategy), and treatment with IMMs after 
discontinuation of anti-TNF therapy.  
The results were expressed as hazard ratios (HRs) with their corresponding 95% CIs. 
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RESULTS 
 
Study population 
The study population comprised 1,055 patients who discontinued anti-TNF drugs after 
achieving clinical remission and met the inclusion criteria. The median follow-up time after 
discontinuation was 19 (6-176) months. The main characteristics of the patients are 
summarized in table 1. Most patients (74%) had received IFX. The reasons for 
discontinuation were elective decision (75%), adverse events (18%), and remission after 
undergoing a top-down strategy (7%). The disease duration in patients undergoing a top-down 
strategy was shorter than in both elective discontinuation and adverse event groups (9.8 
months, 11.9 months, and 13.1 months, respectively; p<0.0001). The median duration of anti-
TNF therapy in the top-down group was shorter than in the other two groups (4 months, 21 
months, and 14 months, respectively; p<0.0001). 
Seventy-two patients treated with IFX received only induction therapy [elective 
discontinuation group: 30/719 (4%) patients; adverse events group: 12/174 (7%) patients; and 
top-down group: 30/68 (44%) patients]. All the patients treated with ADA received induction 
and maintenance therapy. Endoscopy findings at discontinuation were available in 474 
patients (45%); of these, endoscopy findings were normal (ie, no activity was detected) in 419 
(88%). In the remaining 55 patients (12%), endoscopic activity was mild in 38 (69%). After 
discontinuation of anti-TNF drugs, 68% of patients received therapy with immunomodulators 
(IMMs) (thiopurines or methotrexate).  
A total of 460 patients had a normal endoscopy or a normal MRI at the moment of anti-
TNF withdrawal. The main characteristics of this subgroup of patients are summarized in 
table 2.  
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Evolution after discontinuation of anti-TNF therapy 
The incidence of relapse was 18% per patient-year (95% CI=17%-20%). The median time 
to relapse after discontinuation was 11 (1-140) months, and the cumulative incidence of 
relapse was 44% (95% CI=41%-46%): 15% at 6 months, 24% at 1 year, 38% at 2 years, 46% 
at 3 years, and 56% at 5 years after discontinuation. The cumulative incidence of relapse 
during follow-up is shown in figure 1a.  
 
Evolution by type of IBD 
In CD patients, the incidence of relapse was 19% per patient-year (95%CI=17-21%), while 
in UC patients the relapse rate was 17% per patient-year (95%CI=15-20%). Type of IBD was 
not associated with the risk of relapse (p=0.1). The cumulative incidence of relapse by type of 
IBD is shown in figures 1b and 1c. 
The incidence rate of relapse was 17% per patient-year (95%CI=15-18%) when the 
analysis considered only patients receiving IMMs after discontinuation, and 26% per patient-
year (95%CI=22-30%) when the analysis considered only patients who did not continue the 
treatment with IMMs. Among patients who maintained IMMs after discontinuation, the 
cumulative incidence of relapse was 21% at 1 year, 35% at 2 years, 43% at 3 years, and 53% 
at 5 years. From the 32% of patients who did not receive IMMs after withdrawal, 195 had 
CD. Of these, 110 (56%) patients relapsed. The incidence rate of relapse in this group of 
patients was 28% per patient-year (95%CI 24-33%). On the other hand, the incidence rate of 
relapse in CD patients who were under IMMs after withdrawal was 17% per patient-year 
(95%CI 15-19%). Patients who relapsed within 3 months of stopping the anti-TNF therapy 
(early relapse) were more often female (64% vs. 51%, p = 0.03), and had received less 
frequently treatment with IMMs after the withdrawal of the anti-TNF (56% vs. 68%, p = 
0.04). 
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Evolution in patients in deep remission 
In patients in deep remission, the incidence rate of relapse was 19% per patient-year 
(95%CI, 17-22%): 19% per patient-year in CD (95%CI, 16-22%), and 19% per patient-year in 
UC (95%CI, 15-24%). The relapse rate after 1 year of discontinuation was 22% in CD 
patients and 20% in UC patients. 
Predictors of relapse after discontinuation of anti-TNF therapy 
The univariate analysis showed that gender, treatment with IMMs after discontinuation of 
anti-TNF therapy, type of anti-TNF drug received, and reasons for discontinuation (elective 
discontinuation, discontinuation due to adverse events, and discontinuation as part of a top-
down strategy) were the only variables associated with the risk of relapse after 
discontinuation (Figures 2 and 3). No statistical differences were observed in the risk of 
relapse after discontinuation between patients who maintained thiopurines and patients who 
continued methotrexate (41% vs. 45%; p>0.05). 
 In the multivariate analysis (table 3), the variables associated with a higher risk of relapse 
were treatment with ADA vs. IFX (HR=1.29, 95% CI=1.03-1.6), elective discontinuation (vs. 
discontinuation as part of a top-down strategy; HR=1.82, 95% CI=1.19-2.79), and 
discontinuation due to adverse events (vs. the discontinuation as part of a top-down strategy; 
HR=1.95, 95% CI=1.22-3.12). Treatment with IMMs (vs. no treatment) after discontinuation 
and older age at discontinuation (HR=0.99, 95% CI=0.98-0.99) were associated with a lower 
risk of relapse (HR=0.7, 95% CI=0.57-0.88). Gender, type of IBD, current smoking habit, 
prior surgery related to IBD, duration of anti-TNF treatment, and previous treatment with an 
anti-TNF drug had no impact on the risk of relapse.  
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Predictors of relapse by type of IBD 
A subanalysis was performed in patients with UC and CD. In UC, none of the factors was 
statistically significant. In CD, disease localization (colonic vs. ileal) and disease behaviour 
(stricturing vs. inflammatory) were associated with the risk of relapse. Moreover, the 
variables that were significant in the general multivariate analysis were also significant in this 
subanalysis (table 4), adjusted by the duration of anti-TNF treatment. 
A sensitivity analysis was performed with the patients who maintained IMMs after 
discontinuation of anti-TNF. Older age at discontinuation was independently associated with 
a lower risk of relapse (HR=0.98, 95% CI=0.97-9.98). On the other hand, elective 
discontinuation (vs. discontinuation as part of a top-down strategy; HR=1.6, 95% CI=1.06-
2.51) and discontinuation due to adverse events (vs. the discontinuation as part of a top-down 
strategy; HR=1.9, 95% CI=1.14-3.23) were significantly associated with a higher risk of 
relapse. 
The model was also evaluated considering only CD patients who had received the anti-
TNF agent owing to luminal disease (in comparison with UC), and the type of IBD was not 
associated with a higher risk of relapse (HR=1.03, 95% CI=0.79-1.34). Furthermore, we 
repeated the analysis after excluding patients with luminal CD to know whether the risk of 
relapse was higher among patients who received the anti-TNF drug owing to perianal CD in 
comparison with UC and observed that the risk was not increased (HR=1.04, 95% CI=0.77-
1.41).  
In a subanalysis, which included the 444 IBD patients who had undergone endoscopic 
evaluation before discontinuation, and that excluded those with CD in which perianal disease 
was the indication for anti-TNF therapy, the only factor associated with a higher risk of 
relapse was older age at discontinuation (HR=0.98, 95% CI=0.97-0.99). Thus, the presence of 
mucosal lesions in the endoscopy was not associated with a higher risk of relapse after 
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discontinuation. 
 
Predictors of relapse in patients in deep remission 
In the univariate analysis performed in the group of CD patients with clinical remission 
and mucosal healing, the reasons for discontinuation (elective discontinuation, 
discontinuation due to adverse events, and discontinuation as part of a top-down strategy) was 
the only variable associated with the risk of relapse after withdrawal (p<0.0001). In UC 
patients, disease extension (proctitis, left side colitis and extensive colitis) was the only 
variable statistically significant (p=0.002). 
In the multivariate analysis, the only variable associated with a higher risk of relapse in CD 
patients was the discontinuation of anti-TNF treatment due to adverse events (vs. the 
discontinuation as part of a top-down strategy; HR=5.26, 95% CI=1.94-14.27), while older 
age at anti-TNF discontinuation was associated with a lower risk of relapse (HR=0.97, 95% 
CI=0.96-0.99). Gender, type of IBD, current smoking habit, prior surgery related to IBD, 
duration of anti-TNF treatment longer than 2 years, treatment with IMMs after anti-TNF 
discontinuation, and elective discontinuation (vs. discontinuation as a part of top-down 
strategy) were not associated with the risk of relapse. In UC patients, none of these variables 
were associated with the risk of relapse. 
 
Retreatment with anti-TNF drugs after relapse 
Of the 467 (44%) patients who relapsed, 310 (69%) were retreated with the same anti-TNF 
drug, 128 (28%) received another drug, and 14 (3%) were operated on (12 patients had CD 
and 2 patients had UC).  Of the 310 retreated patients, 78% received anti-TNF induction 
therapy. Also, 67% (95% CI=61-72%) of these patients achieved clinical remission after 14 
weeks of treatment. At the end of follow-up, 75% of patients (95% CI=70-80%) were in 
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clinical remission and 13% (95% CI=9-18%) had a partial response (Figure 4a). Clinical 
remission was also achieved at the end of follow-up by 79% of patients (95% CI=72-85%) 
retreated with IFX and 69% of the patients retreated with ADA (95% CI=60-77%).  
Eighty-six out of the 310 patients (28%) restarted anti-TNF in monotherapy. From these 
patients, 53 (62%) achieved clinical remission, and 16 (19%) had a partial response. Patients 
who restarted anti-TNF in monotherapy achieved clinical remission less frequently than those 
who restarted anti-TNF combined with IMMs (68% vs. 78%; p=0.08). The frequency of 
allergic reactions was similar among patients who restarted anti-TNF in monotherapy and 
those who restarted combo therapy (5.2% vs. 5.8%). 
 
Retreatment with anti-TNF drugs after relapse by type of IBD 
Of the 338 CD patients who relapsed, 250 (74%) were retreated with the same anti-TNF, 
74 (22%) were treated with another drug, and 14 (4%) were operated on. In the case of UC 
patients, of the 129 patients who relapsed, 70 (54%) were retreated with the same anti-TNF, 
57 (44%) received another drug, and 2 (2%) were operated on. Response to retreatment by 
type of IBD is shown in figure 4b.  
 
Retreatment with anti-TNF drugs after relapse in patients in deep remission 
Of the 460 patients in deep remission who discontinued the anti-TNF, 177 relapsed. Of 
these, 125 (71%) were retreated with the same anti-TNF, 49 (28%) received another drug, and 
3 (1%) had surgery. At the end of follow-up, 78% (95% CI=70-85%) of the patients were in 
clinical remission and 15% (95% CI=8-20%) had a partial response.  
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Safety of the retreatment after relapse 
After retreatment, 34 of the total of patients who received an anti-TNF drug (11%) 
experienced adverse events. Of these, 16 had infusion reactions, leading to the interruption of 
treatment in 6 cases. Nine patients presented adverse skin reactions but none of them had to 
discontinue treatment. Of the 6 patients who developed infections (2 pharyngitis, 1 varicella, 
1 intra-abdominal abscess, 1 candidal intertrigo, and 1 miliary tuberculosis), 2 had to 
discontinue treatment because of the infection (1 of the patients with pharyngitis and the 
patient with miliary tuberculosis). Finally, 3 patients experienced other types of adverse 
events (dilated cardiomyopathy, memory loss, and leukopenia, respectively) and had to 
discontinue therapy. 
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DISCUSSION 
 
To our knowledge, the cohort analysed in the present study is the largest to date in IBD 
(1,055 patients, median follow-up of 2.4 years) in which the strategy of discontinuing anti-
TNF therapy after clinical remission has been evaluated. We found that the incidence of 
relapse was 18% per patient-year and that the cumulative incidence of relapse was 44% per 
patient-year. These findings confirm the relatively short duration of remission after 
discontinuation of anti-TNF therapy. Other studies have reported similar relapse rates10, 16, 24-27. 
The relapse rate 1 year after discontinuation was 24%, which was slightly lower than in other 
series10, 16, 28, probably because almost all patients in whom endoscopic or radiologic activity 
had been investigated before stopping anti-TNF drugs had inactive disease. In fact, the relapse 
rate within 1 year of discontinuation in this group of patients was 14%. Moreover, endoscopic 
activity was mild in most of the patients in whom activity was detected (12%). Consequently, 
nearly 50% of the patients in our study stopped anti-TNF therapy after having achieved stable 
remission. 
Experience with follow-up periods longer than 1 year after stopping anti-TNFs is very 
limited. A very recent meta-analysis of 27 studies reported an overall risk of relapse of 44% 
in IBD patients who discontinued anti-TNF agents after achieving clinical remission, whereas 
the reported risk of relapse in the long term (≥25 months) was approximately 50%14. 
Therefore, it seems that, over time, a relevant proportion of patients who stopped anti-TNF 
therapy will relapse. However, it is also true that a significant group of patients will maintain 
remission for a long period after stopping treatment. Accordingly, it is essential to identify the 
factors associated with risk of relapse.  
We found that older age at discontinuation was a predictive factor of a lower risk of 
relapse, possibly because younger age has been identified as a predictive factor of poor 
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outcome, since younger patients often have a more aggressive disease course28. Therefore, 
patients diagnosed with IBD at younger ages often begin anti-TNF treatment sooner than 
those diagnosed at older ages28. Indeed, in a recent study, Papamichael et al. followed 100 CD 
patients who discontinued IFX upon achieving clinical remission for a median of 10 years and 
found a risk of relapse of 48%29. Moreover, the authors found that age ≥25 years at diagnosis 
of IBD was the only independent predictive factor for sustained clinical remission after 
discontinuation.  
In the present study, ADA was associated with a higher relapse rate. For many years, IFX 
has been the only anti-TNF agent approved for IBD, thus explaining why ADA has been used 
as the second anti-TNF agent in many patients in whom IFX has previously failed or has lost 
efficacy. However, in the multivariate analysis, treatment with a previous anti-TNF agent was 
not associated with a higher risk of relapse after discontinuation. Finally, this finding could be 
a proxy for undetected variables that were not evaluated and that could be associated with a 
higher risk of relapse after discontinuation of anti-TNF therapy. Nevertheless, even though 
the higher risk of relapse after discontinuation of ADA was statistically significant, its 
magnitude was relatively low (HR=1.29, 95% CI=1.03-1.6) and, therefore, of uncertain 
clinical relevance.  
The top-down strategy (i.e., early introduction of anti-TNF agents combined with 
thiopurines) is frequently used in patients with moderate to severe IBD and with predictive 
factors of poor outcome (e.g., younger age at diagnosis, early need for corticosteroids, 
fistulising phenotype, and perianal disease)30. Patients who discontinue anti-TNF therapy after 
a top-down strategy are usually in stable remission (clinical, endoscopic, radiologic, and 
biochemical) before stopping therapy. Moreover, the rate of mucosal healing has been 
reported to be higher after a top-down strategy than with the conventional step-up approach; 
in addition, the top-down strategy could favour sustained remission4. These observations 
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might explain why, in our study, patients who electively stopped anti-TNF agents and those 
who discontinued treatment owing to adverse events presented a significantly higher risk of 
relapse than those in whom anti-TNF drugs were stopped as part of a top-down strategy. 
Moreover, patients with a top-down approach were always naïve to IMMs. Consequently, 
IMMs alone might have been enough to maintain disease remission in some of these patients 
after stopping anti-TNF therapy. On the contrary, the patients in whom anti-TNF agents had 
been prescribed for a previous failure to IMMs probably have a higher risk of relapse after 
stopping anti-TNFs, even when IMMs are maintained. Although our findings seem logical for 
all the reasons set out above, the small sample size in the top-down group means that our 
results should be treated with caution. 
Almost all the patients who underwent endoscopy before discontinuing anti-TNF drugs 
had inactive disease, although activity was mild in most of those with active disease. These 
findings could be explained by the fact that our study reflects routine clinical practice, in 
which physicians do not usually consider stopping anti-TNF therapy if moderate or severe 
endoscopic activity is detected, even though the patient is asymptomatic. A recent systematic 
review showed that the relapse rate was lower when discontinuation of anti-TNF treatment 
was based on both clinical and endoscopic remission as opposed to clinical remission alone7. 
In this respect, a very recent meta-analysis showed that the incidence of relapse in CD 
patients, in whom the discontinuation of anti-TNF treatment was based exclusively in clinical 
remission, was 42%. Similar findings were observed in UC patients. However, if the anti-
TNF was discontinued in patients in both clinical and endoscopic remission, the relapse rate 
was 26%14. These findings suggest that mucosal healing is a major factor that should be 
evaluated when considering withdrawal of anti-TNF therapy. Nevertheless, other studies, 
including ours, were not able to demonstrate an association between mucosal healing and a 
lower relapse rate, either in CD and UC patients10, 15, 17, 29, 31.  
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As for type of IBD, although some studies found a non-significant trend for longer 
remission in patients with UC11, our results showed no differences in the risk of relapse 
between CD and UC patients, even when we compared luminal and perianal involvement 
separately for both CD and UC.  
Approximately two-thirds of the patients in this cohort maintained IMMs after stopping 
anti-TNF drugs, and this was associated with a lower relapse rate. Not receiving concomitant 
medication with IMMs after stopping anti-TNF treatment has been associated with a higher 
risk of relapse8, 32. IMMs enhance the efficacy of anti-TNF therapy, both in the short term and, 
probably, in the long term; accordingly, concomitant use of anti-TNF drugs with thiopurines, 
regardless of whether they had previously failed, is generally recommended in clinical 
practice33. This beneficial effect of the IMMs might explain the lower risk of relapse in 
patients who maintained these drugs after stopping anti-TNF drugs. Finally, we did not find 
differences in the risk of relapse between patients who maintained thiopurines and those who 
maintained methotrexate, although the sample of the methotrexate group was too small to 
draw definitive conclusions.  
When we performed a multivariate analysis separately for CD, the factors associated with 
the risk of relapse were the same as for the overall IBD patients. Moreover, we found that 
colonic localization (vs. ileal) and stricturing behaviour (vs. inflammatory) were associated 
with a higher risk of relapse. However, these results should be taken with caution as they are 
part of a sensitivity analysis. 
According to our results, retreatment with the same anti-TNF drug in IBD patients who 
relapsed after discontinuation was quite effective, inducing remission in 75% of patients. 
Even though similar findings have been reported in other studies, none has included as large a 
sample as the present study7, 10, 16, 34, 35. The high efficacy of re-initiation of anti-TNF drugs may 
merely reflect the fact that the patients treated with these drugs are a specific group that were 
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previously identified as responders to anti-TNF therapy.  
Patients who restarted anti-TNF in monotherapy achieved clinical remission less 
frequently than those who restarted anti-TNF in combination with IMMs (62% vs. 78%; 
p=0.08). Although this difference was not statistically significant, there was a trend to a lower 
response in patients on anti-TNF in monotherapy. Moreover, in our study, the frequency of 
allergic reactions was similar among patients who restarted anti-TNF in monotherapy and 
those who restarted combo therapy. These findings are in agreement with data reported by 
other authors35. 
Finally, we found that retreatment with the same anti-TNF drug was generally safe. 
However, 34 patients experienced adverse events which led to withdrawal in 11 patients. For 
this reason, the decision of stopping anti-TNF therapy should be individualized, and potential 
consequences (risks and benefits) should always be discussed with the patient. 
Our study has several limitations. First, it is retrospective; therefore, the decision to stop 
anti-TNF agents was based on the subjective criteria of each physician. Moreover, the 
endoscopic scoring system was applied to individual patients reports, and the clinical activity 
scales were calculated reviewing medical records. Second, only half of the patients underwent 
endoscopic assessment at discontinuation. For this reason, and because most of the 
endoscopic lesions, if any, were mild, it was not possible to accurately determine whether 
mucosal healing was a predictor of a lower risk of relapse. However, considering that our 
study reflects daily clinical practice, the fact that a significant proportion of patients had 
undergone endoscopic evaluation was relevant. Furthermore, although laboratory parameters 
were collected from medical records, biochemical data were obtained only in a small number 
of patients.  
One of the strengths of the present study is that—to our knowledge—it was based on the 
largest cohort of patients in whom anti-TNF therapy has been discontinued. In addition, data 
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were collected from 78 Spanish hospitals, and the follow-up period was long, with a 
considerable number of patients followed for more than 5 years. 
In conclusion, the results of this large multicentre study showed that approximately half of 
the patients who discontinued anti-TNF agents because of clinical remission relapse after 
discontinuation. We found that treatment with ADA, elective discontinuation of anti-TNF 
drugs, and discontinuation due to adverse events (vs. top-down strategy) were associated with 
a higher risk of relapse after discontinuation. On the contrary, the maintenance of treatment 
with IMMs and older age at discontinuation are associated with a lower risk of relapse. Based 
on these findings, discontinuation of anti-TNF therapy cannot be universally recommended in 
routine clinical practice. However, it seems that some patients can stop anti-TNF therapy 
safely and remain in remission for long periods. The decision whether to continue with anti-
TNF drugs should be taken on an individual basis and discussed with the patient. If the drug 
is discontinued and the patient with IBD relapses, the response to retreatment with the same 
anti-TNF is usually effective and safe. 
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Table 1. Baseline characteristics of the patients. 
 
Variables Total CD UC 
Type of disease, n (%) 1.055 (100) 731 (69) 324 (31) 
Male, n (%) 526 (49.9) 349 (47.7) 177 (54.6) 
Mean age at diagnosis, years (range) 30 (6-76) 29 (6-76) 35 (9-71) 
Mean age at discontinuation, years (range) 38 (13-82) 37 (13-82) 42 (16-79) 
Mean age, years (range) 42 (17-85) 41 (17-85) 46 (17-82) 
Extra-intestinal manifestations, n (%) 287 (27) 217 (29.9) 70 (21.7) 
Current smokers, n (%) 239 (24) 203 (29) 36 (11.4) 
History of abdominal surgery, n (%) 248 (24) 238 (32.8) 10 (3.2) 
Type of anti-TNF therapy, n (%) 
-IFX 
-ADA  
 
781 (74) 
274 (26) 
 
485 (66.3) 
246 (33.7) 
 
296 (91.4) 
28 (8.6) 
Treatment following anti-TNF withdrawal, n (%) 
-Thiopurines 
-MTX 
-5-ASA 
-None 
 
689 (65) 
29 (3) 
149 (14) 
188 (18) 
 
480 (65.7) 
22 (3) 
65 (8.9) 
164 (22.4) 
 
209 (64.5) 
7 (2.2) 
84 (25.9) 
24 (7.4) 
Endoscopy at the moment of anti-TNF withdrawal, n (%) 
-Endoscopic activity  
-Mild activity 
-Moderate activity 
-Severe activity 
-Unknown grade of activity 
474 (45) 
55 (12) 
38 (69) 
4 (7) 
2 (4) 
11 (20) 
279 (58.9) 
 
10 (3.6) 
2 (0.7) 
1 (2.5) 
7 (2.5) 
195 (41.1) 
 
28 (14.4) 
2 (1) 
1 (2.1) 
4 (2.1) 
Montreal location at CD diagnosis, n (%) 
-L1 (ileal) 
-L2 (colonic) 
-L3 (ileocolonic) 
-L4 (upper gastrointestinal tract) 
 
200 (27.4) 
159 (21.7) 
371 (50.7) 
1 (0.2) 
  
Montreal behaviour at CD diagnosis, n (%) 
-B1 (inflammatory) 
-B2 (stricturing) 
-B3 (penetrating) 
-Unknown 
 
432 (59) 
126 (17) 
161 (22) 
12 (2) 
  
Perianal disease, n (%) 277 (38)   
UC extension, n (%)  
-Proctitis 
-Left side colitis 
-Extensive colitis 
 
19 (6) 
108 (33) 
197 (61) 
  
CD with MRI at the moment of anti-TNF withdrawal, n  
-Radiological activity, n (%) 
88 
9 (10) 
  
CD: Crohn’s disease; UC: ulcerative colitis; IMMs: immunomodulators; MTX: methotrexate; 5-ASA: 5-
aminosalicylates; IFX: infliximab; ADA: adalimumab; MRI: magnetic resonance imaging. 
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Table 2. Baseline characteristics of the patients in deep remission at the moment of anti-TNF 
discontinuation. 
 
Variables Total CD UC 
Type of disease, n (%) 460 (100) 300 (65.2) 160 (34.8) 
Male, n (%) 235 (51.1) 143 (47.7) 92 (58) 
Mean age at diagnosis, years (range) 31 (7-70) 29 (7-69) 34 (9-70) 
Mean age at discontinuation, years (range) 38 (15-80) 36 (15-80) 42 (16-74) 
Mean age, years (range) 42 (17-82) 40 (17-82) 45 (18-75) 
Extra-intestinal manifestations, n (%) 103 (22.5) 70 (23.5) 33 (20.6) 
Current smokers, n (%) 87 (19.3) 69 (23.6) 18 (11.4) 
History of abdominal surgery, n (%) 104 (23) 101 (66) 3 (1.8) 
Type of anti-TNF therapy, n (%) 
-IFX 
-ADA  
 
335 (72.8) 
125 (27.2) 
 
189 (63) 
111 (37) 
 
146 (91.3) 
14 (8.8) 
Anti-TNF longer than 2 years before withdrawal 193 (45.8) 127 (48) 66 (43) 
Reasons to discontinue anti-TNF therapy 
-Elective decision 
-Top down strategy 
-Adverse events 
 
400 (87) 
24 (5.2) 
36 (7.8) 
 
255 (85) 
20 (6.7) 
25 (8.3) 
 
145 (90.6) 
4 (2.5) 
11 (6.9) 
Treatment following anti-TNF withdrawal, n (%) 
-Thiopurines 
-MTX 
-5-ASA 
-None 
 
345 (75) 
9 (2) 
66 (14.3) 
40 (8.7) 
 
232 (77.3) 
6 (2) 
23 (7.7) 
39 (13) 
 
113 (70.6) 
3 (1.9) 
43 (26.9) 
1 (0.6) 
Montreal location at CD diagnosis, n (%) 
-L1 (ileal) 
-L2 (colonic) 
-L3 (ileocolonic) 
 
 
74 (24.7) 
78 (26) 
148 (49.3) 
 
  
Montreal behaviour at CD diagnosis, n (%) 
-B1 (inflammatory) 
-B2 (stricturing) 
-B3 (penetrating) 
-Unknown 
 
176 (58.7) 
55 (18.3) 
66 (22) 
3 (1) 
  
Perianal disease, n (%) 113 (37.6)   
UC extension, n (%)  
-Proctitis 
-Left side colitis 
-Extensive colitis 
 
7 (4.4) 
57 (5.6) 
96 (60) 
  
CD: Crohn’s disease; UC: ulcerative colitis; IMMs: immunomodulators; MTX: methotrexate; 5-ASA: 5-
aminosalicylates; IFX: infliximab; ADA: adalimumab; MRI: magnetic resonance imaging. 
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Table 3. Factors associated with the risk of relapse after discontinuation of anti-TNF therapy 
in the multivariate analysis. 
Factors HR 95% CI P-value 
Maintenance of IMMs after 
discontinuation  
0.70 0.57-0.88 0.002 
Older age at discontinuation 0.99 0.98-0.99 <0.0001 
Treatment with ADA (vs. IFX) 1.29 1.03-1.60 0.027 
Elective discontinuation (vs. 
discontinuation for top-down 
strategy) 
1.82 1.19-2.79 0.006 
Discontinuation due to adverse 
events (vs. discontinuation as part 
of a top-down strategy) 
1.95 1.22-3.12 0.005 
HR: hazard ratio; IMMs: immunomodulators; ADA: adalimumab; IFX: infliximab; CI: 
confidence interval. 
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Table 4. Factors associated with the risk of relapse after discontinuation of anti-TNF therapy 
in the multivariate analysis in CD. 
 
Factors HR 95% CI P-value 
Maintenance of IMMs after 
discontinuation*  
0.67 0.51-0.87 0.003 
Older age at discontinuation* 0.98 0.97-0.99 0.001 
Treatment with ADA (vs. IFX)* 1.29 1.01-1.66 0.04 
Elective discontinuation (vs. 
discontinuation for top-down 
strategy)* 
1.90 1.07-3.37 0.03 
Discontinuation due to adverse 
events (vs. discontinuation as part of 
a top-down strategy)* 
2.33 1.27-4.29 0.006 
Colonic localization (vs. ileal)* 1.51 1.13-2.02 0.005 
Stricturing behaviour (vs. 
inflammatory)* 
1.50 1.09-2.05 0.01 
HR: hazard ratio; IMMs: immunomodulators; ADA: adalimumab; IFX: infliximab; CI: 
confidence interval. 
 (*) adjusted by duration of anti-TNF therapy 
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Figure legends: 
Figure 1a. Kaplan-Meier curve showing the probability of survival without relapse after 
discontinuation of anti-TNF therapy for the whole study cohort. 
Figure 1b. Kaplan-Meier curve showing the probability of survival without relapse after 
discontinuation of anti-TNF therapy for Crohn’s disease patients.  
Figure 1c. Kaplan-Meier curve showing the probability of survival without relapse after 
discontinuation of anti-TNF therapy for ulcerative colitis patients. 
Figure 2. Kaplan-Meier curves showing the risk of relapse in patients treated vs. not treated 
with immunomodulators after discontinuation of anti-TNF therapy.  
Figure 3. Kaplan-Meier curves showing the risk of relapse depending on the reason for 
discontinuation of anti-TNF therapy. 
Figure 4a. Response to the retreatment with the same anti-TNF in patients who relapsed after 
discontinuing anti-TNF therapy. 
Figure 4b. Response to the retreatment with the same anti-TNF at the end of follow-up in 
Crohn’s disease and ulcerative colitis patients who relapsed after discontinuing anti-TNF 
therapy. 
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STUDY HIGHLIGHTS 
Current Knowledge 
• The risk of relapse after anti-TNF withdrawal are not well known.
• The variables that impact clinical course after withdrawal are not well known.
• The efficacy and safety of retreatment with the same anti-TNF drug in patients who
relapse seem to be high.
• Currently available data are insufficient to make recommendations on when anti-TNF
therapy can be stopped.
What is new here 
• Approximately half of the patients who discontinued anti-TNF agents because of
clinical remission relapse after discontinuation.
• Treatment with ADA, elective discontinuation of anti-TNF drugs, and discontinuation
due to adverse events increase the risk of relapse.
• Treatment with IMMs and older age at discontinuation are associated with a lower risk
of relapse.
• Discontinuation of anti-TNF therapy cannot be universally recommended. However,
some patients can stop anti-TNF therapy safely and remain in remission for long
periods.
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SUMMARY 
 
AIMS: To assess the risk of relapse after discontinuation of anti-TNF drugs in patients 
with inflammatory bowel disease, to identify the factors associated with relapse, and to 
evaluate the response to and safety of retreatment with the same anti-TNF after relapsing. 
METHODS: Retrospective, observational, multicentre study. Patients with Crohn’s 
disease or ulcerative colitis who had been treated with anti-TNFs and in whom these drugs 
were discontinued after clinical remission was achieved were included.  
RESULTS: 1,055 patients were included. The cumulative incidence of relapse was 44%: 
24% at 1 year, 38% at 2 years, 46% at 3 years, and 56% at 5 years after anti-TNF 
discontinuation. The incidence rate of relapse was 18% per patient-year. The variables 
associated with a higher risk of relapse were treatment with adalimumab vs. infliximab 
(HR=1.29;95%CI=1.03-1.60) and elective discontinuation of anti-TNFs 
(HR=1.82;95%CI=1.19-2.79) or discontinuation due to adverse events 
(HR=1.95;95%CI=1.22-3.12) vs. a top-down strategy. Treatment with immunomodulators 
after discontinuation (HR=0.70;95%CI=0.57-0.88) and age (HR=0.99;95%CI=0.98-0.99) 
were associated with a lower risk of relapse. Retreatment of relapse with the same anti-TNF 
was effective (88% responded) and safe. 
CONCLUSIONS: The incidence rate of relapse after anti-TNF discontinuation in patients 
with inflammatory bowel disease who were in remission was 18% per patient-year. Treatment 
with adalimumab, the elective discontinuation of anti-TNFs, or discontinuation of anti-TNFs 
due to adverse events (vs. top-down strategy) increased the risk of relapse. Older age and 
maintenance treatment with immunomodulators were associated with a lower risk of relapse. 
Retreatment with the same anti-TNF drug was effective and safe. 
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INTRODUCTION 
 
Anti-tumour necrosis factor-α (anti-TNF) drugs are effective in inducing and maintaining 
remission in patients with inflammatory bowel diseases (IBD), namely, Crohn's disease (CD) 
and ulcerative colitis (UC)1. This effectiveness is associated with mucosal healing, improved 
quality of life, fewer hospitalizations, and reduced need for surgical procedures1-4. 
Discontinuation of anti-TNF treatment can be considered once remission has been 
achieved. The decision to discontinue anti-TNF drugs in patients in remission depends on 
several factors, such as the cost of the medications, the potential but serious adverse effects, 
and the outcome following elective withdrawal5. Once it has been decided that the drug is to 
be withdrawn, the optimal time for doing so must be established6.  
Studies evaluating this strategy are mostly single-cohort designs, and most of them include 
a small number of patients and have a short follow-up period7. Therefore, the risk of relapse 
after withdrawal of anti-TNF medication and the variables that impact clinical course after 
withdrawal are not well known. Data from small observational studies of patients who 
discontinued anti-TNF therapy after having achieved clinical remission show that the range of 
relapse rates is wide8-14.  
The retreatment with the same anti-TNF drug in patients ho relapse after the initial 
withdrawal have been reported to be apparently successful and safe12, 15-17, and these factors are 
essential before deciding whether to discontinue anti-TNF therapy. However, there are many 
concerns relating to discontinuation of anti-TNF therapy in IBD patients that include not only 
the risk of relapse, but the possible loss of efficacy when the drug is restarted, the risk of 
infusion reactions and other adverse events at retreatment, and, finally, the possibility of 
losing therapeutic options. Therefore, currently available data are insufficient to make 
recommendations on when, if ever, anti-TNF therapy can be stopped in patients with IBD.  
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The aims of the present study were to assess the risk of relapse after discontinuation of anti-
TNF therapy, to identify the factors associated with relapse, to know the rate of response to 
retreatment with the same anti-TNF drug after relapsing, and to evaluate the safety of retreatment 
with these drugs. 
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METHODS 
Study population 
The present study was a multicentre, observational, retrospective study conducted at 78 
Spanish centres. The study population comprised patients diagnosed with CD or UC who had 
been treated with anti-TNF agents (infliximab [IFX] or adalimumab [ADA]) to induce 
remission and in whom these drugs had been discontinued after clinical remission was 
achieved. The reasons for discontinuation of anti-TNF treatment were as follows: elective 
decision (by the physician and/or by the patient), onset of adverse events, and early 
introduction of thiopurines combined with an anti-TNF agent in order to induce clinical 
remission of IBD in patients who were naïve to immunosuppressive therapy (top-down 
strategy). The minimum requirement for all patients was to have received induction treatment 
with anti-TNF drugs. The patients were followed for a minimum of 6 months after stopping 
treatment. Patients who had been treated with anti-TNF drugs for reasons other than IBD or 
with less than 6 months of follow-up after discontinuation was excluded. If the patients had 
more than one attempt to stop the anti-TNF treatment, only the first attempt to discontinue 
this drug was included in analysis. 
Ethical aspects 
The study was approved by the respective institutional ethics review boards, and was 
conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines. 
Data collection 
All clinical, endoscopic, and radiological data were obtained from medical records. The 
data collected included demographic data, duration of IBD, smoking habits, previous surgery 
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for IBD, and previous IBD treatments (eg, immunosuppressants). Clinical, endoscopic, 
laboratory, and radiological data were collected at 3 different times during follow-up: at 
discontinuation of the anti-TNF drug, when the patient relapsed (if this occurred), and at the 
last follow-up visit. It was considered that the patient had an endoscopy or a MRI at the 
moment of withdrawal if these procedures were performed within 30 days before anti-TNF 
discontinuation. Information about the response to treatment after re-introduction of anti-TNF 
therapy in relapsing patients and occurrence of adverse events after reintroduction were also 
recorded.  
Study data were collected and managed using REDCap electronic data capture tools hosted 
at Asociación Española de Gastroenterología (AEG; www.aegastro.es)18. AEG is a non-profit 
Scientific and Medical Society focused on Gastroenterology, and it provided this service free 
of charge, with the sole aim of promoting independent investigator driven research. REDCap 
(Research Electronic Data Capture) is a secure, web-based application designed to support 
data capture for research studies, providing 1) an intuitive interface for validated data entry; 
2) audit trails for tracking data manipulation and export procedures; 3) automated export 
procedures for seamless data downloads to common statistical packages; and 4) procedures 
for importing data from external sources.  
 
Definitions 
Clinical remission: For luminal CD, remission was defined as a Harvey-Bradshaw index 
score ≤ 4 points19. For UC, remission was defined as a partial Mayo score ≤ 2 points20.  In the 
case of perianal disease, remission was defined as the absence of fistula drainage despite 
gentle finger compression (Fistula Drainage Assessment score)21. Given the retrospective 
nature of the study, Harvey-Bradshaw index and partial Mayo score were estimated after 
reviewing the medical records.  
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Endoscopic inflammation: In the case of luminal CD, endoscopic activity was classified 
as mild, moderate, severe, or mucosal healing, as judged by the investigators based on the 
findings in the endoscopy report.  
Given the retrospective design of the study, it was not feasible to calculate endoscopic 
scores based on the endoscopy records. The Rutgeerts index was used to categorize the 
severity of post-surgical recurrence22. Endoscopic inflammation in UC patients was classified 
using the endoscopic subscore of the Mayo index, that was applied retrospectively to 
individual patient reports23. 
Radiological remission: For perianal CD, the disease was considered to be in remission if 
pelvic magnetic resonance imaging (MRI) demonstrated that the perianal fistulas tracts 
showed no signs of activity and were without local complications. In the case of luminal CD 
patients, the disease was considered to be inactive if the abdominal MRI did not show 
contrast enhancement of the wall, oedema, or ulcers.  
Relapse: As this is a retrospective study, relapse was defined as the onset of documented 
clinical, biochemical, endoscopic, or radiological activity leading to a therapeutic 
intervention, namely, escalation or modification of medical therapy or surgery for disease 
control.  
Response to re-treatment: In patients with luminal CD, remission was defined as a 
Harvey-Bradshaw index ≤ 4 points: a partial response was defined as a decrease ≥ 3 points 
from baseline. In fistulising CD, remission was defined as cessation of spontaneous fistula 
drainage and lack of drainage after gentle finger compression, while a decrease from baseline 
in the number of open draining fistulae of ≥ 50% or a reduction in fistula drainage were 
considered partial response. In UC patients, remission was defined as a partial Mayo score ≤ 2 
points, whereas a decrease of ≥ 3 points from baseline was considered a partial response. 
Response to retreatment with anti-TNF therapy was evaluated at 2 time points: 14 weeks 
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(initial response) and the end of follow-up (final response). 
 
Statistical analysis 
The descriptive analysis of quantitative variables included the mean and standard deviation 
or the median and interquartile range, depending on whether the variables were normally 
distributed or not. For the categorical variables, the percentage and the 95% confidence 
intervals (95% CIs) were provided. Comparisons between means were performed using the t 
test for independent samples. Categorical variables were compared using the χ2 test and the 
Fisher exact test or the Wilcoxon rank-sum test according to the distribution of data. 
Statistical significance was set at P < 0.05.  
Long-term maintenance of remission was estimated using Kaplan-Meier curves. Survival 
curves assessing the impact of several variables on long-term remission were compared using 
the log-rank test. A Cox regression model was constructed to identify predictive factors for 
relapse. All the variables that reached statistical significance in the univariate analysis and 
those that were considered clinically relevant were included in the multivariate analysis. The 
dependent variable was the risk of relapse after discontinuation of anti-TNF therapy. The 
independent variables were: type of IBD (CD and UC), gender, age at discontinuation 
(included as a continuous variable), surgery due to IBD, current smoking habit, type of anti-
TNF drug received (IFX or ADA), duration of anti-TNF treatment, reasons for anti-TNF 
discontinuation (elective discontinuation, discontinuation due to adverse events, and 
discontinuation as a part of a top-down strategy), and treatment with IMMs after 
discontinuation of anti-TNF therapy.  
The results were expressed as hazard ratios (HRs) with their corresponding 95% CIs. 
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RESULTS 
 
Study population 
The study population comprised 1,055 patients who discontinued anti-TNF drugs after 
achieving clinical remission and met the inclusion criteria. The median follow-up time after 
discontinuation was 19 (6-176) months. The main characteristics of the patients are 
summarized in table 1. Most patients (74%) had received IFX. The reasons for 
discontinuation were elective decision (75%), adverse events (18%), and remission after 
undergoing a top-down strategy (7%). The disease duration in patients undergoing a top-down 
strategy was shorter than in both elective discontinuation and adverse event groups (9.8 
months, 11.9 months, and 13.1 months, respectively; p<0.0001). The median duration of anti-
TNF therapy in the top-down group was shorter than in the other two groups (4 months, 21 
months, and 14 months, respectively; p<0.0001). 
Seventy-two patients treated with IFX received only induction therapy [elective 
discontinuation group: 30/719 (4%) patients; adverse events group: 12/174 (7%) patients; and 
top-down group: 30/68 (44%) patients]. All the patients treated with ADA received induction 
and maintenance therapy. Endoscopy findings at discontinuation were available in 474 
patients (45%); of these, endoscopy findings were normal (ie, no activity was detected) in 419 
(88%). In the remaining 55 patients (12%), endoscopic activity was mild in 38 (69%). After 
discontinuation of anti-TNF drugs, 68% of patients received therapy with immunomodulators 
(IMMs) (thiopurines or methotrexate).  
A total of 460 patients had a normal endoscopy or a normal MRI at the moment of anti-
TNF withdrawal. The main characteristics of this subgroup of patients are summarized in 
table 2.  
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Evolution after discontinuation of anti-TNF therapy 
The incidence of relapse was 18% per patient-year (95% CI=17%-20%). The median time 
to relapse after discontinuation was 11 (1-140) months, and the cumulative incidence of 
relapse was 44% (95% CI=41%-46%): 15% at 6 months, 24% at 1 year, 38% at 2 years, 46% 
at 3 years, and 56% at 5 years after discontinuation. The cumulative incidence of relapse 
during follow-up is shown in figure 1a.  
 
Evolution by type of IBD 
In CD patients, the incidence of relapse was 19% per patient-year (95%CI=17-21%), while 
in UC patients the relapse rate was 17% per patient-year (95%CI=15-20%). Type of IBD was 
not associated with the risk of relapse (p=0.1). The cumulative incidence of relapse by type of 
IBD is shown in figures 1b and 1c. 
The incidence rate of relapse was 17% per patient-year (95%CI=15-18%) when the 
analysis considered only patients receiving IMMs after discontinuation, and 26% per patient-
year (95%CI=22-30%) when the analysis considered only patients who did not continue the 
treatment with IMMs. Among patients who maintained IMMs after discontinuation, the 
cumulative incidence of relapse was 21% at 1 year, 35% at 2 years, 43% at 3 years, and 53% 
at 5 years. From the 32% of patients who did not receive IMMs after withdrawal, 195 had 
CD. Of these, 110 (56%) patients relapsed. The incidence rate of relapse in this group of 
patients was 28% per patient-year (95%CI 24-33%). On the other hand, the incidence rate of 
relapse in CD patients who were under IMMs after withdrawal was 17% per patient-year 
(95%CI 15-19%). Patients who relapsed within 3 months of stopping the anti-TNF therapy 
(early relapse) were more often female (64% vs. 51%, p = 0.03), and had received less 
frequently treatment with IMMs after the withdrawal of the anti-TNF (56% vs. 68%, p = 
0.04). 
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Evolution in patients in deep remission 
In patients in deep remission, the incidence rate of relapse was 19% per patient-year 
(95%CI, 17-22%): 19% per patient-year in CD (95%CI, 16-22%), and 19% per patient-year in 
UC (95%CI, 15-24%). The relapse rate after 1 year of discontinuation was 22% in CD 
patients and 20% in UC patients. 
 
Predictors of relapse after discontinuation of anti-TNF therapy 
The univariate analysis showed that gender, treatment with IMMs after discontinuation of 
anti-TNF therapy, type of anti-TNF drug received, and reasons for discontinuation (elective 
discontinuation, discontinuation due to adverse events, and discontinuation as part of a top-
down strategy) were the only variables associated with the risk of relapse after 
discontinuation (Figures 2 and 3). No statistical differences were observed in the risk of 
relapse after discontinuation between patients who maintained thiopurines and patients who 
continued methotrexate (41% vs. 45%; p>0.05). 
 In the multivariate analysis (table 3), the variables associated with a higher risk of relapse 
were treatment with ADA vs. IFX (HR=1.29, 95% CI=1.03-1.6), elective discontinuation (vs. 
discontinuation as part of a top-down strategy; HR=1.82, 95% CI=1.19-2.79), and 
discontinuation due to adverse events (vs. the discontinuation as part of a top-down strategy; 
HR=1.95, 95% CI=1.22-3.12). Treatment with IMMs (vs. no treatment) after discontinuation 
and older age at discontinuation (HR=0.99, 95% CI=0.98-0.99) were associated with a lower 
risk of relapse (HR=0.7, 95% CI=0.57-0.88). Gender, type of IBD, current smoking habit, 
prior surgery related to IBD, duration of anti-TNF treatment, and previous treatment with an 
anti-TNF drug had no impact on the risk of relapse.  
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Predictors of relapse by type of IBD 
A subanalysis was performed in patients with UC and CD. In UC, none of the factors was 
statistically significant. In CD, disease localization (colonic vs. ileal) and disease behaviour 
(stricturing vs. inflammatory) were associated with the risk of relapse. Moreover, the 
variables that were significant in the general multivariate analysis were also significant in this 
subanalysis (table 4), adjusted by the duration of anti-TNF treatment. 
A sensitivity analysis was performed with the patients who maintained IMMs after 
discontinuation of anti-TNF. Older age at discontinuation was independently associated with 
a lower risk of relapse (HR=0.98, 95% CI=0.97-9.98). On the other hand, elective 
discontinuation (vs. discontinuation as part of a top-down strategy; HR=1.6, 95% CI=1.06-
2.51) and discontinuation due to adverse events (vs. the discontinuation as part of a top-down 
strategy; HR=1.9, 95% CI=1.14-3.23) were significantly associated with a higher risk of 
relapse. 
The model was also evaluated considering only CD patients who had received the anti-
TNF agent owing to luminal disease (in comparison with UC), and the type of IBD was not 
associated with a higher risk of relapse (HR=1.03, 95% CI=0.79-1.34). Furthermore, we 
repeated the analysis after excluding patients with luminal CD to know whether the risk of 
relapse was higher among patients who received the anti-TNF drug owing to perianal CD in 
comparison with UC and observed that the risk was not increased (HR=1.04, 95% CI=0.77-
1.41).  
In a subanalysis, which included the 444 IBD patients who had undergone endoscopic 
evaluation before discontinuation, and that excluded those with CD in which perianal disease 
was the indication for anti-TNF therapy, the only factor associated with a higher risk of 
relapse was older age at discontinuation (HR=0.98, 95% CI=0.97-0.99). Thus, the presence of 
mucosal lesions in the endoscopy was not associated with a higher risk of relapse after 
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discontinuation. 
 
Predictors of relapse in patients in deep remission 
In the univariate analysis performed in the group of CD patients with clinical remission 
and mucosal healing, the reasons for discontinuation (elective discontinuation, 
discontinuation due to adverse events, and discontinuation as part of a top-down strategy) was 
the only variable associated with the risk of relapse after withdrawal (p<0.0001). In UC 
patients, disease extension (proctitis, left side colitis and extensive colitis) was the only 
variable statistically significant (p=0.002). 
In the multivariate analysis, the only variable associated with a higher risk of relapse in CD 
patients was the discontinuation of anti-TNF treatment due to adverse events (vs. the 
discontinuation as part of a top-down strategy; HR=5.26, 95% CI=1.94-14.27), while older 
age at anti-TNF discontinuation was associated with a lower risk of relapse (HR=0.97, 95% 
CI=0.96-0.99). Gender, type of IBD, current smoking habit, prior surgery related to IBD, 
duration of anti-TNF treatment longer than 2 years, treatment with IMMs after anti-TNF 
discontinuation, and elective discontinuation (vs. discontinuation as a part of top-down 
strategy) were not associated with the risk of relapse. In UC patients, none of these variables 
were associated with the risk of relapse. 
 
Retreatment with anti-TNF drugs after relapse 
Of the 467 (44%) patients who relapsed, 310 (69%) were retreated with the same anti-TNF 
drug, 128 (28%) received another drug, and 14 (3%) were operated on (12 patients had CD 
and 2 patients had UC).  Of the 310 retreated patients, 78% received anti-TNF induction 
therapy. Also, 67% (95% CI=61-72%) of these patients achieved clinical remission after 14 
weeks of treatment. At the end of follow-up, 75% of patients (95% CI=70-80%) were in 
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clinical remission and 13% (95% CI=9-18%) had a partial response (Figure 4a). Clinical 
remission was also achieved at the end of follow-up by 79% of patients (95% CI=72-85%) 
retreated with IFX and 69% of the patients retreated with ADA (95% CI=60-77%).  
Eighty-six out of the 310 patients (28%) restarted anti-TNF in monotherapy. From these 
patients, 53 (62%) achieved clinical remission, and 16 (19%) had a partial response. Patients 
who restarted anti-TNF in monotherapy achieved clinical remission less frequently than those 
who restarted anti-TNF combined with IMMs (68% vs. 78%; p=0.08). The frequency of 
allergic reactions was similar among patients who restarted anti-TNF in monotherapy and 
those who restarted combo therapy (5.2% vs. 5.8%). 
 
Retreatment with anti-TNF drugs after relapse by type of IBD 
Of the 338 CD patients who relapsed, 250 (74%) were retreated with the same anti-TNF, 
74 (22%) were treated with another drug, and 14 (4%) were operated on. In the case of UC 
patients, of the 129 patients who relapsed, 70 (54%) were retreated with the same anti-TNF, 
57 (44%) received another drug, and 2 (2%) were operated on. Response to retreatment by 
type of IBD is shown in figure 4b.  
 
Retreatment with anti-TNF drugs after relapse in patients in deep remission 
Of the 460 patients in deep remission who discontinued the anti-TNF, 177 relapsed. Of 
these, 125 (71%) were retreated with the same anti-TNF, 49 (28%) received another drug, and 
3 (1%) had surgery. At the end of follow-up, 78% (95% CI=70-85%) of the patients were in 
clinical remission and 15% (95% CI=8-20%) had a partial response.  
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Safety of the retreatment after relapse 
After retreatment, 34 of the total of patients who received an anti-TNF drug (11%) 
experienced adverse events. Of these, 16 had infusion reactions, leading to the interruption of 
treatment in 6 cases. Nine patients presented adverse skin reactions but none of them had to 
discontinue treatment. Of the 6 patients who developed infections (2 pharyngitis, 1 varicella, 
1 intra-abdominal abscess, 1 candidal intertrigo, and 1 miliary tuberculosis), 2 had to 
discontinue treatment because of the infection (1 of the patients with pharyngitis and the 
patient with miliary tuberculosis). Finally, 3 patients experienced other types of adverse 
events (dilated cardiomyopathy, memory loss, and leukopenia, respectively) and had to 
discontinue therapy. 
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DISCUSSION 
 
To our knowledge, the cohort analysed in the present study is the largest to date in IBD 
(1,055 patients, median follow-up of 2.4 years) in which the strategy of discontinuing anti-
TNF therapy after clinical remission has been evaluated. We found that the incidence of 
relapse was 18% per patient-year and that the cumulative incidence of relapse was 44% per 
patient-year. These findings confirm the relatively short duration of remission after 
discontinuation of anti-TNF therapy. Other studies have reported similar relapse rates10, 16, 24-27. 
The relapse rate 1 year after discontinuation was 24%, which was slightly lower than in other 
series10, 16, 28, probably because almost all patients in whom endoscopic or radiologic activity 
had been investigated before stopping anti-TNF drugs had inactive disease. In fact, the relapse 
rate within 1 year of discontinuation in this group of patients was 14%. Moreover, endoscopic 
activity was mild in most of the patients in whom activity was detected (12%). Consequently, 
nearly 50% of the patients in our study stopped anti-TNF therapy after having achieved stable 
remission. 
Experience with follow-up periods longer than 1 year after stopping anti-TNFs is very 
limited. A very recent meta-analysis of 27 studies reported an overall risk of relapse of 44% 
in IBD patients who discontinued anti-TNF agents after achieving clinical remission, whereas 
the reported risk of relapse in the long term (≥25 months) was approximately 50%14. 
Therefore, it seems that, over time, a relevant proportion of patients who stopped anti-TNF 
therapy will relapse. However, it is also true that a significant group of patients will maintain 
remission for a long period after stopping treatment. Accordingly, it is essential to identify the 
factors associated with risk of relapse.  
We found that older age at discontinuation was a predictive factor of a lower risk of 
relapse, possibly because younger age has been identified as a predictive factor of poor 
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outcome, since younger patients often have a more aggressive disease course28. Therefore, 
patients diagnosed with IBD at younger ages often begin anti-TNF treatment sooner than 
those diagnosed at older ages28. Indeed, in a recent study, Papamichael et al. followed 100 CD 
patients who discontinued IFX upon achieving clinical remission for a median of 10 years and 
found a risk of relapse of 48%29. Moreover, the authors found that age ≥25 years at diagnosis 
of IBD was the only independent predictive factor for sustained clinical remission after 
discontinuation.  
In the present study, ADA was associated with a higher relapse rate. For many years, IFX 
has been the only anti-TNF agent approved for IBD, thus explaining why ADA has been used 
as the second anti-TNF agent in many patients in whom IFX has previously failed or has lost 
efficacy. However, in the multivariate analysis, treatment with a previous anti-TNF agent was 
not associated with a higher risk of relapse after discontinuation. Finally, this finding could be 
a proxy for undetected variables that were not evaluated and that could be associated with a 
higher risk of relapse after discontinuation of anti-TNF therapy. Nevertheless, even though 
the higher risk of relapse after discontinuation of ADA was statistically significant, its 
magnitude was relatively low (HR=1.29, 95% CI=1.03-1.6) and, therefore, of uncertain 
clinical relevance.  
The top-down strategy (i.e., early introduction of anti-TNF agents combined with 
thiopurines) is frequently used in patients with moderate to severe IBD and with predictive 
factors of poor outcome (e.g., younger age at diagnosis, early need for corticosteroids, 
fistulising phenotype, and perianal disease)30. Patients who discontinue anti-TNF therapy after 
a top-down strategy are usually in stable remission (clinical, endoscopic, radiologic, and 
biochemical) before stopping therapy. Moreover, the rate of mucosal healing has been 
reported to be higher after a top-down strategy than with the conventional step-up approach; 
in addition, the top-down strategy could favour sustained remission4. These observations 
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might explain why, in our study, patients who electively stopped anti-TNF agents and those 
who discontinued treatment owing to adverse events presented a significantly higher risk of 
relapse than those in whom anti-TNF drugs were stopped as part of a top-down strategy. 
Moreover, patients with a top-down approach were always naïve to IMMs. Consequently, 
IMMs alone might have been enough to maintain disease remission in some of these patients 
after stopping anti-TNF therapy. On the contrary, the patients in whom anti-TNF agents had 
been prescribed for a previous failure to IMMs probably have a higher risk of relapse after 
stopping anti-TNFs, even when IMMs are maintained. Although our findings seem logical for 
all the reasons set out above, the small sample size in the top-down group means that our 
results should be treated with caution. 
Almost all the patients who underwent endoscopy before discontinuing anti-TNF drugs 
had inactive disease, although activity was mild in most of those with active disease. These 
findings could be explained by the fact that our study reflects routine clinical practice, in 
which physicians do not usually consider stopping anti-TNF therapy if moderate or severe 
endoscopic activity is detected, even though the patient is asymptomatic. A recent systematic 
review showed that the relapse rate was lower when discontinuation of anti-TNF treatment 
was based on both clinical and endoscopic remission as opposed to clinical remission alone7. 
In this respect, a very recent meta-analysis showed that the incidence of relapse in CD 
patients, in whom the discontinuation of anti-TNF treatment was based exclusively in clinical 
remission, was 42%. Similar findings were observed in UC patients. However, if the anti-
TNF was discontinued in patients in both clinical and endoscopic remission, the relapse rate 
was 26%14. These findings suggest that mucosal healing is a major factor that should be 
evaluated when considering withdrawal of anti-TNF therapy. Nevertheless, other studies, 
including ours, were not able to demonstrate an association between mucosal healing and a 
lower relapse rate, either in CD and UC patients10, 15, 17, 29, 31.  
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As for type of IBD, although some studies found a non-significant trend for longer 
remission in patients with UC11, our results showed no differences in the risk of relapse 
between CD and UC patients, even when we compared luminal and perianal involvement 
separately for both CD and UC.  
Approximately two-thirds of the patients in this cohort maintained IMMs after stopping 
anti-TNF drugs, and this was associated with a lower relapse rate. Not receiving concomitant 
medication with IMMs after stopping anti-TNF treatment has been associated with a higher 
risk of relapse8, 32. IMMs enhance the efficacy of anti-TNF therapy, both in the short term and, 
probably, in the long term; accordingly, concomitant use of anti-TNF drugs with thiopurines, 
regardless of whether they had previously failed, is generally recommended in clinical 
practice33. This beneficial effect of the IMMs might explain the lower risk of relapse in 
patients who maintained these drugs after stopping anti-TNF drugs. Finally, we did not find 
differences in the risk of relapse between patients who maintained thiopurines and those who 
maintained methotrexate, although the sample of the methotrexate group was too small to 
draw definitive conclusions.  
When we performed a multivariate analysis separately for CD, the factors associated with 
the risk of relapse were the same as for the overall IBD patients. Moreover, we found that 
colonic localization (vs. ileal) and stricturing behaviour (vs. inflammatory) were associated 
with a higher risk of relapse. However, these results should be taken with caution as they are 
part of a sensitivity analysis. 
According to our results, retreatment with the same anti-TNF drug in IBD patients who 
relapsed after discontinuation was quite effective, inducing remission in 75% of patients. 
Even though similar findings have been reported in other studies, none has included as large a 
sample as the present study7, 10, 16, 34, 35. The high efficacy of re-initiation of anti-TNF drugs may 
merely reflect the fact that the patients treated with these drugs are a specific group that were 
Page 55 of 75
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
American Journal of Gastroenterology
For Peer Review
 22
previously identified as responders to anti-TNF therapy.  
Patients who restarted anti-TNF in monotherapy achieved clinical remission less 
frequently than those who restarted anti-TNF in combination with IMMs (62% vs. 78%; 
p=0.08). Although this difference was not statistically significant, there was a trend to a lower 
response in patients on anti-TNF in monotherapy. Moreover, in our study, the frequency of 
allergic reactions was similar among patients who restarted anti-TNF in monotherapy and 
those who restarted combo therapy. These findings are in agreement with data reported by 
other authors35. 
Finally, we found that retreatment with the same anti-TNF drug was generally safe. 
However, 34 patients experienced adverse events which led to withdrawal in 11 patients. For 
this reason, the decision of stopping anti-TNF therapy should be individualized, and potential 
consequences (risks and benefits) should always be discussed with the patient. 
Our study has several limitations. First, it is retrospective; therefore, the decision to stop 
anti-TNF agents was based on the subjective criteria of each physician. Moreover, the 
endoscopic scoring system was applied to individual patients reports, and the clinical activity 
scales were calculated reviewing medical records. Second, only half of the patients underwent 
endoscopic assessment at discontinuation. For this reason, and because most of the 
endoscopic lesions, if any, were mild, it was not possible to accurately determine whether 
mucosal healing was a predictor of a lower risk of relapse. However, considering that our 
study reflects daily clinical practice, the fact that a significant proportion of patients had 
undergone endoscopic evaluation was relevant. Furthermore, although laboratory parameters 
were collected from medical records, biochemical data were obtained only in a small number 
of patients.  
One of the strengths of the present study is that—to our knowledge—it was based on the 
largest cohort of patients in whom anti-TNF therapy has been discontinued. In addition, data 
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were collected from 78 Spanish hospitals, and the follow-up period was long, with a 
considerable number of patients followed for more than 5 years. 
In conclusion, the results of this large multicentre study showed that approximately half of 
the patients who discontinued anti-TNF agents because of clinical remission relapse after 
discontinuation. We found that treatment with ADA, elective discontinuation of anti-TNF 
drugs, and discontinuation due to adverse events (vs. top-down strategy) were associated with 
a higher risk of relapse after discontinuation. On the contrary, the maintenance of treatment 
with IMMs and older age at discontinuation are associated with a lower risk of relapse. Based 
on these findings, discontinuation of anti-TNF therapy cannot be universally recommended in 
routine clinical practice. However, it seems that some patients can stop anti-TNF therapy 
safely and remain in remission for long periods. The decision whether to continue with anti-
TNF drugs should be taken on an individual basis and discussed with the patient. If the drug 
is discontinued and the patient with IBD relapses, the response to retreatment with the same 
anti-TNF is usually effective and safe. 
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Table 1. Baseline characteristics of the patients. 
 
Variables Total CD UC 
Type of disease, n (%) 1.055 (100) 731 (69) 324 (31) 
Male, n (%) 526 (49.9) 349 (47.7) 177 (54.6) 
Mean age at diagnosis, years (range) 30 (6-76) 29 (6-76) 35 (9-71) 
Mean age at discontinuation, years (range) 38 (13-82) 37 (13-82) 42 (16-79) 
Mean age, years (range) 42 (17-85) 41 (17-85) 46 (17-82) 
Extra-intestinal manifestations, n (%) 287 (27) 217 (29.9) 70 (21.7) 
Current smokers, n (%) 239 (24) 203 (29) 36 (11.4) 
History of abdominal surgery, n (%) 248 (24) 238 (32.8) 10 (3.2) 
Type of anti-TNF therapy, n (%) 
-IFX 
-ADA  
 
781 (74) 
274 (26) 
 
485 (66.3) 
246 (33.7) 
 
296 (91.4) 
28 (8.6) 
Treatment following anti-TNF withdrawal, n (%) 
-Thiopurines 
-MTX 
-5-ASA 
-None 
 
689 (65) 
29 (3) 
149 (14) 
188 (18) 
 
480 (65.7) 
22 (3) 
65 (8.9) 
164 (22.4) 
 
209 (64.5) 
7 (2.2) 
84 (25.9) 
24 (7.4) 
Endoscopy at the moment of anti-TNF withdrawal, n (%) 
-Endoscopic activity  
-Mild activity 
-Moderate activity 
-Severe activity 
-Unknown grade of activity 
474 (45) 
55 (12) 
38 (69) 
4 (7) 
2 (4) 
11 (20) 
279 (58.9) 
 
10 (3.6) 
2 (0.7) 
1 (2.5) 
7 (2.5) 
195 (41.1) 
 
28 (14.4) 
2 (1) 
1 (2.1) 
4 (2.1) 
Montreal location at CD diagnosis, n (%) 
-L1 (ileal) 
-L2 (colonic) 
-L3 (ileocolonic) 
-L4 (upper gastrointestinal tract) 
 
200 (27.4) 
159 (21.7) 
371 (50.7) 
1 (0.2) 
  
Montreal behaviour at CD diagnosis, n (%) 
-B1 (inflammatory) 
-B2 (stricturing) 
-B3 (penetrating) 
-Unknown 
 
432 (59) 
126 (17) 
161 (22) 
12 (2) 
  
Perianal disease, n (%) 277 (38)   
UC extension, n (%)  
-Proctitis 
-Left side colitis 
-Extensive colitis 
 
19 (6) 
108 (33) 
197 (61) 
  
CD with MRI at the moment of anti-TNF withdrawal, n  
-Radiological activity, n (%) 
88 
9 (10) 
  
CD: Crohn’s disease; UC: ulcerative colitis; IMMs: immunomodulators; MTX: methotrexate; 5-ASA: 5-
aminosalicylates; IFX: infliximab; ADA: adalimumab; MRI: magnetic resonance imaging. 
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Table 2. Baseline characteristics of the patients in deep remission at the moment of anti-TNF 
discontinuation. 
 
Variables Total CD UC 
Type of disease, n (%) 460 (100) 300 (65.2) 160 (34.8) 
Male, n (%) 235 (51.1) 143 (47.7) 92 (58) 
Mean age at diagnosis, years (range) 31 (7-70) 29 (7-69) 34 (9-70) 
Mean age at discontinuation, years (range) 38 (15-80) 36 (15-80) 42 (16-74) 
Mean age, years (range) 42 (17-82) 40 (17-82) 45 (18-75) 
Extra-intestinal manifestations, n (%) 103 (22.5) 70 (23.5) 33 (20.6) 
Current smokers, n (%) 87 (19.3) 69 (23.6) 18 (11.4) 
History of abdominal surgery, n (%) 104 (23) 101 (66) 3 (1.8) 
Type of anti-TNF therapy, n (%) 
-IFX 
-ADA  
 
335 (72.8) 
125 (27.2) 
 
189 (63) 
111 (37) 
 
146 (91.3) 
14 (8.8) 
Anti-TNF longer than 2 years before withdrawal 193 (45.8) 127 (48) 66 (43) 
Reasons to discontinue anti-TNF therapy 
-Elective decision 
-Top down strategy 
-Adverse events 
 
400 (87) 
24 (5.2) 
36 (7.8) 
 
255 (85) 
20 (6.7) 
25 (8.3) 
 
145 (90.6) 
4 (2.5) 
11 (6.9) 
Treatment following anti-TNF withdrawal, n (%) 
-Thiopurines 
-MTX 
-5-ASA 
-None 
 
345 (75) 
9 (2) 
66 (14.3) 
40 (8.7) 
 
232 (77.3) 
6 (2) 
23 (7.7) 
39 (13) 
 
113 (70.6) 
3 (1.9) 
43 (26.9) 
1 (0.6) 
Montreal location at CD diagnosis, n (%) 
-L1 (ileal) 
-L2 (colonic) 
-L3 (ileocolonic) 
 
 
74 (24.7) 
78 (26) 
148 (49.3) 
 
  
Montreal behaviour at CD diagnosis, n (%) 
-B1 (inflammatory) 
-B2 (stricturing) 
-B3 (penetrating) 
-Unknown 
 
176 (58.7) 
55 (18.3) 
66 (22) 
3 (1) 
  
Perianal disease, n (%) 113 (37.6)   
UC extension, n (%)  
-Proctitis 
-Left side colitis 
-Extensive colitis 
 
7 (4.4) 
57 (5.6) 
96 (60) 
  
CD: Crohn’s disease; UC: ulcerative colitis; IMMs: immunomodulators; MTX: methotrexate; 5-ASA: 5-
aminosalicylates; IFX: infliximab; ADA: adalimumab; MRI: magnetic resonance imaging. 
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Table 3. Factors associated with the risk of relapse after discontinuation of anti-TNF therapy 
in the multivariate analysis. 
 
Factors HR 95% CI P-value 
Maintenance of IMMs after 
discontinuation  
0.70 0.57-0.88 0.002 
Older age at discontinuation 0.99 0.98-0.99 <0.0001 
Treatment with ADA (vs. IFX) 1.29 1.03-1.60 0.027 
Elective discontinuation (vs. 
discontinuation for top-down 
strategy) 
1.82 1.19-2.79 0.006 
Discontinuation due to adverse 
events (vs. discontinuation as part 
of a top-down strategy) 
1.95 1.22-3.12 0.005 
HR: hazard ratio; IMMs: immunomodulators; ADA: adalimumab; IFX: infliximab; CI: 
confidence interval. 
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Table 4. Factors associated with the risk of relapse after discontinuation of anti-TNF therapy 
in the multivariate analysis in CD. 
 
Factors HR 95% CI P-value 
Maintenance of IMMs after 
discontinuation*  
0.67 0.51-0.87 0.003 
Older age at discontinuation* 0.98 0.97-0.99 0.001 
Treatment with ADA (vs. IFX)* 1.29 1.01-1.66 0.04 
Elective discontinuation (vs. 
discontinuation for top-down 
strategy)* 
1.90 1.07-3.37 0.03 
Discontinuation due to adverse 
events (vs. discontinuation as part of 
a top-down strategy)* 
2.33 1.27-4.29 0.006 
Colonic localization (vs. ileal)* 1.51 1.13-2.02 0.005 
Stricturing behaviour (vs. 
inflammatory)* 
1.50 1.09-2.05 0.01 
HR: hazard ratio; IMMs: immunomodulators; ADA: adalimumab; IFX: infliximab; CI: 
confidence interval. 
 (*) adjusted by duration of anti-TNF therapy 
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Figure legends: 
Figure 1a. Kaplan-Meier curve showing the probability of survival without relapse after 
discontinuation of anti-TNF therapy for the whole study cohort. 
Figure 1b. Kaplan-Meier curve showing the probability of survival without relapse after 
discontinuation of anti-TNF therapy for Crohn’s disease patients.  
Figure 1c. Kaplan-Meier curve showing the probability of survival without relapse after 
discontinuation of anti-TNF therapy for ulcerative colitis patients. 
Figure 2. Kaplan-Meier curves showing the risk of relapse in patients treated vs. not treated 
with immunomodulators after discontinuation of anti-TNF therapy.  
Figure 3. Kaplan-Meier curves showing the risk of relapse depending on the reason for 
discontinuation of anti-TNF therapy. 
Figure 4a. Response to the retreatment with the same anti-TNF in patients who relapsed after 
discontinuing anti-TNF therapy. 
Figure 4b. Response to the retreatment with the same anti-TNF at the end of follow-up in 
Crohn’s disease and ulcerative colitis patients who relapsed after discontinuing anti-TNF 
therapy. 
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Figure 1a. Kaplan-Meier curve showing the probability of survival without relapse after discontinuation of 
anti-TNF therapy for the whole study cohort.  
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Figure 1b. Kaplan-Meier curve showing the probability of survival without relapse after discontinuation of 
anti-  TNF therapy for Crohn’s disease patients.   
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Figure 1c. Kaplan-Meier curve showing the probability of survival without relapse after discontinuation of 
anti-TNF therapy for ulcerative colitis patients.  
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Figure 2. Kaplan-Meier curves showing the risk of relapse in patients treated vs. not treated with 
immunomodulators after discontinuation of anti-TNF therapy.  
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Figure 3. Kaplan-Meier curves showing the risk of relapse depending on the reason for discontinuation of 
anti-TNF therapy.  
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Figure 4a. Response to the retreatment with the same anti-TNF in patients who relapsed after 
discontinuing anti-TNF therapy. 
 
 
 
 
 
67%
n=193
75%
n=211
25%
n=73
13%
n=378%
n=22
12%
n=33
0
10
20
30
40
50
60
70
80
90
100
Response at 14 weeks Response at the end of follow-up
%
Remission
Partial response
Non-response
Page 74 of 75
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
American Journal of Gastroenterology
For Peer Review
Figure 4b. Response to the retreatment with the same anti-TNF at the end of follow-up in 
Crohn’s disease and ulcerative colitis patients who relapsed after discontinuing anti-TNF 
therapy. 
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